Rasool N - Search Results

1

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).

Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N, Rose PG. Simpkins F, et al. Among authors: rasool n. Gynecol Oncol. 2015 Feb;136(2):240-5. doi: 10.1016/j.ygyno.2014.12.004. Epub 2014 Dec 6. Gynecol Oncol. 2015. PMID: 25485782 Clinical Trial.

2

Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.

Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, Rose PG, O'Malley DM. Rasool N, et al. Gynecol Oncol. 2010 Jan;116(1):10-4. doi: 10.1016/j.ygyno.2009.10.043. Epub 2009 Oct 28. Gynecol Oncol. 2010. PMID: 19875158

3

Fertility-preserving surgical procedures for patients with gynecologic malignancies.

Rasool N, Rose PG. Rasool N, et al. Clin Obstet Gynecol. 2010 Dec;53(4):804-14. doi: 10.1097/GRF.0b013e3181f97d02. Clin Obstet Gynecol. 2010. PMID: 21048447 Review.

4

Single-port laparoscopic pelvic and para-aortic lymph node sampling or lymphadenectomy: development of a technique and instrumentation.

Escobar PF, Fader AN, Rasool N, Espalliat LR. Escobar PF, et al. Among authors: rasool n. Int J Gynecol Cancer. 2010 Oct;20(7):1268-73. doi: 10.1111/IGC.0b013e3181ea7f5d. Int J Gynecol Cancer. 2010. PMID: 21119563

5

CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.

Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L, Belinson JL, Ganapathi MK, Ganapathi R. Fader AN, et al. Among authors: rasool n. Anticancer Res. 2010 Dec;30(12):4791-8. Anticancer Res. 2010. PMID: 21187454

6

Is time to recurrence after hysterectomy predictive of survival in patients with early stage endometrial carcinoma?

Robbins JR, Yechieli R, Laser B, Mahan M, Rasool N, Elshaikh MA. Robbins JR, et al. Among authors: rasool n. Gynecol Oncol. 2012 Oct;127(1):38-42. doi: 10.1016/j.ygyno.2012.06.042. Epub 2012 Jul 11. Gynecol Oncol. 2012. PMID: 22796549

7

Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.

Devoogdt N, Rasool N, Hoskins E, Simpkins F, Tchabo N, Kohn EC. Devoogdt N, et al. Among authors: rasool n. Cancer Sci. 2009 Mar;100(3):434-40. doi: 10.1111/j.1349-7006.2009.01076.x. Epub 2009 Jan 14. Cancer Sci. 2009. PMID: 19154415 Free PMC article.

8

The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.

Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM, Kohn EC. Simpkins FA, et al. Among authors: rasool n. Carcinogenesis. 2008 Mar;29(3):466-72. doi: 10.1093/carcin/bgm212. Epub 2007 Oct 4. Carcinogenesis. 2008. PMID: 17916899

9

Influence of Comorbidity on the Risk of Death: A Single Institution Study of 1132 Women With Early-stage Uterine Cancer.

Elshaikh MA, Vance S, Kamal M, Burmeister C, Hanna RK, Rasool N, Siddiqui F. Elshaikh MA, et al. Among authors: rasool n. Am J Clin Oncol. 2017 Apr;40(2):183-188. doi: 10.1097/COC.0000000000000129. Am J Clin Oncol. 2017. PMID: 25222075

10

Adjuvant radiation therapy for patients with type II endometrial carcinoma: impact on tumor recurrence and survival.

Yechieli R, Rasool N, Robbins JR, Cogan CM, Elshaikh MA. Yechieli R, et al. Among authors: rasool n. Int J Gynecol Cancer. 2013 May;23(4):763-8. doi: 10.1097/IGC.0b013e31828b15cb. Int J Gynecol Cancer. 2013. PMID: 23485931

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters